Recent news focuses on BridgeBio's successes in ATTR-CM with acoramidis and LGMD2I/R9 with BBP-418, but there is no recent information on a Phase 3 win in thyroid disorders.
Recent news focuses on BridgeBio's successes in ATTR-CM with acoramidis and LGMD2I/R9 with BBP-418, but there is no recent information on a Phase 3 win in thyroid disorders.